Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 11 min ago
Peer-reviewedCC BYFrontiers in cell and developmental biology

Pyroptosis in myocardial ischemia-reperfusion injury: mechanistic pathways and therapeutic prospects.

  1. 1Department of Cardiology, Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
  2. 2Department of General Practice, Xi'an Daxing Hospital, Xian, China.

Abstract

Acute myocardial infarction (AMI) remains the leading cause of cardiovascular death and disability worldwide. With the advances in percutaneous coronary intervention and coronary artery bypass grafting, timely revascularization has become the main approach to limit infarct size and improve heart function and prognosis. However, the sudden restoration of blood flow during reperfusion can actually accelerate heart muscle cell death by worsening inflammation, calcium overload, and oxidative stress, a phenomenon known as myocardial ischemia-reperfusion injury (MIRI). Pyroptosis, a lytic and highly pro-inflammatory form of programmed cell death executed by members of the gasdermin family, has emerged as a central mechanism linking cell death to inflammation in MIRI. This review summarizes the molecular pathways of pyroptosis, including the canonical NLRP3/caspase-1/GSDMD axis, non-canonical caspase-4/5/11 activation, and the caspase-3/GSDME pathway, and profiles the roles of individual gasdermin family members in MIRI. We then delineate how pyroptosis operates in cardiomyocytes, cardiac fibroblasts, vascular endothelial cells, and macrophages; how it is modulated by oxidative stress, calcium overload, and autophagy. We further evaluate therapeutic agents acting at distinct nodes of this cascade, including NLRP3 inhibitors, caspase inhibitors, GSDMD inhibitors, repurposed drugs, and natural products, and assess the experimental models and levels of evidence supporting them. We conclude that pyroptosis is a promising therapeutic target for MIRI. Nevertheless, the available evidence is still dominated by preclinical studies of GSDMD, and several issues remain unresolved, including cell type-specific regulatory mechanisms, the roles of gasdermin family members beyond GSDMD, and key translational challenges.

Related

  1. TRPV4-linked oxidative–lysosomal stress in myocardial ischemia/reperfusion: disease-matched transcriptomics and functional analysis in OGD/R cardiomyoblasts
    Jie Yang, Jincheng Li, Guanyao Li +12
    Frontiers in cell and developmental biologyPeer-reviewedCC BYFull textGeneral biochemistryEurope PMC
  2. HSP90B1 exacerbates myocardial infarction injury by promoting cardiomyocyte pyroptosis and is associated with M1-like macrophage polarization
    Yemin Wang, Jiaqian Ge, Ying Zhang +9
    Biology DirectPeer-reviewedCC BY-NC-ND 4.0Full textMolecular biology & gene regulationPMC
  3. Mechanistic Study of GSDME and CXCL10 in SUV39H1-Mediated Pyroptosis and Immune Suppression in Cervical Cancer.
    Li Zhang, Peiting Sheng, Dongge Cai +3
    Cancer medicinePeer-reviewedCC BY-NCFull textMolecular biology & gene regulationEurope PMCPMC
  4. Unraveling the pyroptosis-mitophagy axis: from molecular mechanisms to therapeutic opportunities
    Jiaqi Ban, Ranxing Chen, Lihong Ao +4
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationCrossrefEurope PMCPMC
  5. Extracellular Vesicles in Molecular Crosstalk and Disease Pathogenesis: A Comprehensive Review on Mechanisms and Therapeutic Prospects
    Shana Balachandran, Madan Kumar Arumugam, Rakhee Rathnam Kalari Kandy +5
    Biochemical pharmacologyPeer-reviewedLicence not statedFull text2 citedMolecular biology & gene regulationPMC
BibTeX
@article{ding2026pyroptosis,
  title = {{Pyroptosis in myocardial ischemia-reperfusion injury: mechanistic pathways and therapeutic prospects.}},
  author = {Shenshen Ding and Xiaoding Zhang and Zuxian Sheng and Yuanyuan Wang and Wuwang Fang},
  journal = {Frontiers in cell and developmental biology},
  year = {2026},
  month = oct,
  doi = {10.3389/fcell.2026.1938791},
  url = {https://europepmc.org/article/MED/42948070},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Pyroptosis in myocardial ischemia-reperfusion injury: mechanistic pathways and therapeutic prospects.
AU  - Shenshen Ding
AU  - Xiaoding Zhang
AU  - Zuxian Sheng
AU  - Yuanyuan Wang
AU  - Wuwang Fang
PY  - 2026
DA  - 2026/10/13
JO  - Frontiers in cell and developmental biology
DO  - 10.3389/fcell.2026.1938791
UR  - https://europepmc.org/article/MED/42948070
AB  - Acute myocardial infarction (AMI) remains the leading cause of cardiovascular death and disability worldwide. With the advances in percutaneous coronary intervention and coronary artery bypass grafting, timely revascularization has become the main approach to limit infarct size and improve heart function and prognosis. However, the sudden restoration of blood flow during reperfusion can actually accelerate heart muscle cell death by worsening inflammation, calcium overload, and oxidative stress, a phenomenon known as myocardial ischemia-reperfusion injury (MIRI). Pyroptosis, a lytic and highly pro-inflammatory form of programmed cell death executed by members of the gasdermin family, has emerged as a central mechanism linking cell death to inflammation in MIRI. This review summarizes the molecular pathways of pyroptosis, including the canonical NLRP3/caspase-1/GSDMD axis, non-canonical caspase-4/5/11 activation, and the caspase-3/GSDME pathway, and profiles the roles of individual gasdermin family members in MIRI. We then delineate how pyroptosis operates in cardiomyocytes, cardiac fibroblasts, vascular endothelial cells, and macrophages; how it is modulated by oxidative stress, calcium overload, and autophagy. We further evaluate therapeutic agents acting at distinct nodes of this cascade, including NLRP3 inhibitors, caspase inhibitors, GSDMD inhibitors, repurposed drugs, and natural products, and assess the experimental models and levels of evidence supporting them. We conclude that pyroptosis is a promising therapeutic target for MIRI. Nevertheless, the available evidence is still dominated by preclinical studies of GSDMD, and several issues remain unresolved, including cell type-specific regulatory mechanisms, the roles of gasdermin family members beyond GSDMD, and key translational challenges.
SN  - 2296-634X
ER  -